We serve Chemical Name:2-methyldodec-1-ene CAS:16435-49-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-methyldodec-1-ene
CAS.NO:16435-49-7
Synonyms:2-methyl-dodec-1-ene;2-Methyl-dodec-1-en;2-Methyl-1-dodecene;1-Dodecene,2-methyl
Molecular Formula:C13H26
Molecular Weight:182.34600
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:229.7ºC at 760mmHg
Density:0.766g/cm3
Index of Refraction:1.432
PSA:
Exact Mass:182.20300
LogP:5.09330
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-methyl-dodec-1-ene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Dodecene,2-methyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Methyl-1-dodecene Use and application,2-Methyl-1-dodecene technical grade,usp/ep/jp grade.
Related News: And finally, CHMP also concluded its investigation into bluebird bio’s Zynteglo, finding no evidence that it causes a blood cancer known as acute myeloid leukemia. 4-Amino-2-methyl-octadecan-5-ol; compound with oxalic acid manufacturers During Covid-19, the company has helped fill a void in meeting API demand for medicines used to treat patients with the virus. In April of last year, Wavelength expanded its production of API for three generic drugs— sedative midazolam, muscle relaxant cisatracurium, and paralytic rocuronium — to help keep up with hospital demand. Repressor (Escherichia coli strain D816 clone pJL9 gene pacRreduced) suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. methyl (3S,7R,8R,10S,13S,14S)-3-((methoxycarbonyl)oxy)-10,13-dimethyl-17-oxo-2,3,4,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-7-carboxylate vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. methyl (3S,7R,8R,10S,13S,14S)-3-((methoxycarbonyl)oxy)-10,13-dimethyl-17-oxo-2,3,4,7,8,10,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-7-carboxylate vendor & factory.
